Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HX008 + Irinotecan |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HX008 | HX-008|HX 008|Pucotenlimab | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | HX008 is a monoclonal antibody that binds to PD-1 (PDCD1) and blocks its interaction with PD-L1 (CD274) and PD-L2 (PDCD1LG2), inhibiting downstream signaling and potentially leading to activation of T-cell-mediated immune response against tumor cells and inhibition of tumor growth (PMID: 32106752). | |
Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|